In the Media

Companies pair up to take Rett Syndrome program into clinic - July 20, 2017

https://www.thepharmaletter.com/article/companies-pair-up-to-take-rett-syndrome-program-into-clinic/

 

News of Note—Trevena CMO exit; AMO deal; Kala IPO; AliveCor-Mayo pact - July 20, 2017

http://www.fiercebiotech.com/biotech/news-note-trevena-cmo-exit-amo-deal-kala-ipo-alivecor-mayo-pact

 

FDA Gives Fast Track Status to Potential Therapy for Congenital Myotonic Dystrophy - June 1, 2017

https://musculardystrophynews.com/2017/06/01/amo-02-congenital-myotonic-dystrophy-treatment-gains-fda-fast-track/

 

AMO Pharma receives FDA Fast Track Status - May 30, 2017

http://european-biotechnology.com/up-to-date/latest-news/news/amo-pharma-receives-fda-fast-track-status.html


FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford - May 30, 2017

http://labiotech.eu/amo-pharma-amo-02-myotonic-dystrophy/

 

AMO Pharma Addresses Rare Childhood Disease - May 22, 2017

https://www.clinicalleader.com/doc/amo-pharma-addresses-rare-childhood-disease-0001

 

Ranedis and AMO Partner to Develop HDAC Inhibitor for Rare Genetic Diseases - March 14, 2017

http://www.genengnews.com/gen-news-highlights/ranedis-and-amo-partner-to-develop-hdac-inhibitor-for-rare-genetic-diseases/81254020

 

AMO Pharma and Ranedis target rare genetic diseases in RND-001 deal - March 14, 2017

https://www.thepharmaletter.com/article/amo-pharma-and-ranedis-target-rare-genetic-diseases-in-rnd-001-deal

 

Wayne-Based AMO Pharma Raises $25 Million - October 1, 2015

https://patch.com/pennsylvania/te/wayne-based-amo-pharma-raises-25-million

 

Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma - October 1, 2015

http://labiotech.eu/neil-woodford-amo-pharma-25m/


Subscribe
Stay updated about AMO! Enter your information here to receive updates about AMO Pharma via email:



Unsubscribe
To unsubscribe from all AMO Pharma communications, please click here.